226 related articles for article (PubMed ID: 28507809)
1. T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces
Inderberg EM; Wälchli S; Myhre MR; Trachsel S; Almåsbak H; Kvalheim G; Gaudernack G
Oncoimmunology; 2017; 6(4):e1302631. PubMed ID: 28507809
[TBL] [Abstract][Full Text] [Related]
2. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
3. A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells.
Saeterdal I; Gjertsen MK; Straten P; Eriksen JA; Gaudernack G
Cancer Immunol Immunother; 2001 Nov; 50(9):469-76. PubMed ID: 11761441
[TBL] [Abstract][Full Text] [Related]
4. [The relationship between frameshift mutations of transforming growth factor-beta type II receptor, insulin growth factor II receptor, bcl-2 associated X protein, E2F4 and microsatellite instability in gastric carcinoma].
Chen GT; Zhu ZG; Yin HR; Liu BY; Ji J; Zhang J; Lin YZ
Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(5):344-8. PubMed ID: 16635398
[TBL] [Abstract][Full Text] [Related]
5. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.
Linnebacher M; Gebert J; Rudy W; Woerner S; Yuan YP; Bork P; von Knebel Doeberitz M
Int J Cancer; 2001 Jul; 93(1):6-11. PubMed ID: 11391614
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
[TBL] [Abstract][Full Text] [Related]
7. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
8. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
9. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
[TBL] [Abstract][Full Text] [Related]
10. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
Maletzki C; Schmidt F; Dirks WG; Schmitt M; Linnebacher M
Eur J Cancer; 2013 Jul; 49(11):2587-95. PubMed ID: 23561850
[TBL] [Abstract][Full Text] [Related]
11. Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma.
Ren L; Leisegang M; Deng B; Matsuda T; Kiyotani K; Kato T; Harada M; Park JH; Saloura V; Seiwert T; Vokes E; Agrawal N; Nakamura Y
Oncoimmunology; 2019; 8(4):e1568813. PubMed ID: 30906664
[TBL] [Abstract][Full Text] [Related]
12. PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer.
Li Q; Liu M; Wu M; Zhou X; Wang S; Hu Y; Wang Y; He Y; Zeng X; Chen J; Liu Q; Xiao D; Hu X; Liu W
Oncol Lett; 2018 Apr; 15(4):5924-5932. PubMed ID: 29556312
[TBL] [Abstract][Full Text] [Related]
13. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen.
Mami-Chouaib F; Echchakir H; Dorothée G; Vergnon I; Chouaib S
Immunol Rev; 2002 Oct; 188():114-21. PubMed ID: 12445285
[TBL] [Abstract][Full Text] [Related]
14. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
[TBL] [Abstract][Full Text] [Related]
15. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
Wang QJ; Yu Z; Griffith K; Hanada K; Restifo NP; Yang JC
Cancer Immunol Res; 2016 Mar; 4(3):204-14. PubMed ID: 26701267
[TBL] [Abstract][Full Text] [Related]
16. Restoring TGFbeta function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation.
Warusavitarne J; McDougall F; de Silva K; Barnetson R; Messina M; Robinson BG; Schnitzler M
Int J Colorectal Dis; 2009 Feb; 24(2):139-44. PubMed ID: 18985362
[TBL] [Abstract][Full Text] [Related]
17. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
18. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
19. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
20. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
